Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 156Lymphoma, Non-Hodgkin 141Leukemia, Lymphocytic, Chronic, B-Cell 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Follicular 112Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Mantle-Cell 75Lymphoma, B-Cell 73Hodgkin Disease 63Multiple Myeloma 59Leukemia 55Burkitt Lymphoma 51Recurrence 49Lymphoma, B-Cell, Marginal Zone 48Leukemia, Myeloid, Acute 47Neoplasms 45Myelodysplastic Syndromes 42Hematologic Neoplasms 34Waldenstrom Macroglobulinemia 28Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Lymphoma, T-Cell 17Leukemia, Biphenotypic, Acute 16Leukemia, B-Cell 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Mycosis Fungoides 15Lymphoproliferative Disorders 15Lymphoma, T-Cell, Peripheral 15Myeloproliferative Disorders 14Lymphoma, T-Cell, Cutaneous 14Breast Neoplasms 14

Interventions

Rituximab 1Lenalidomide 1CT-P10 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Composite Lymphoma × Lymphoid × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡